This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This Advisory is based on TIP 27, Comprehensive Case Management for Substance Abuse Treatment. It surveys the underlying principles and models of case management, discusses reasons substance use disorder (SUD) treatment providers might consider implementing or expanding the use of case management, and lists some case management-related resources and tools.

This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in substance use disorder (SUD) treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.

This Advisory is based on TIP 53, Addressing Viral Hepatitis in People with Substance Use Disorders. It offers guidance to providers and administrators in substance use disorder treatment programs on screening for, and treating clients with, hepatitis A, hepatitis B, and hepatitis C infections.

This Advisory is based on TIP 31, Screening and Assessing Adolescents for Substance Use Disorders (SUDs) and TIP 32, Treatment of Adolescents with SUDs. It includes recommendations for engaging adolescents in SUD risk assessment, screening, and treatment.

This Advisory is based on TIP 37, Substance Abuse Treatment for Persons With HIV/AIDS. It highlights strategies and considerations for substance use disorder (SUD) treatment providers to effectively engage people with HIV in SUD treatment.

This Advisory is based on TIP 50, Addressing Suicidal Thoughts and Behaviors in Substance Abuse Treatment. It provides strategies for identifying and addressing suicidal thoughts and behaviors among individuals with substance use disorders (SUDs).

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.

This advisory reviews diabetes and how it relates to mental illness, stress, and substance use disorders. It highlights ways to integrate diabetes care into behavioral health treatment, such as screening and intake, staff education, integrated care, and counseling support.